Full Text:

Machine learning algorithms can sometimes do a great job with a little help from human expertise, at least in the field of materials science. In many specialized areas of science, engineering and medicine, researchers are turning to machine learning algorithms to analyze data sets that have grown too large for humans to understand. In materials science, success with this effort could accelerate the design of next-generation advanced functional materials, where development now usually depends on old-fashioned trial and error. By themselves, however, data analytics techniques borrowed from other research areas often fail to provide the insights needed to help materials scientists and engineers choose which of many variables to adjust -- and the techniques can't account for dramatic changes such as the introduction of a new chemical compound into the process. In a new study, researchers explain a technique known as dimensional stacking, which shows that human experience still has a role to play in the age of machine intelligence. The machines gain an edge at solving a challenge when the data to be analyzed are intelligently organized based on human knowledge of what factors are likely to be important and related. "When your machine accepts strings of data, it really does matter how you are putting those strings together," said Nazanin Bassiri-Gharb, the paper's corresponding author and a scientist at the Georgia Institute of Technology. "We must be mindful that the organization of data before it goes to the algorithm makes a difference. If you don't plug the information in correctly, you will get a result that isn't necessarily correlated with the reality of the physics and chemistry that govern the materials."

Image credit: Rob Felt/Georgia Tech

Source: Ed Arce 10/09/2024

H.C. Wainwright & Co. analysts Ed Arce and Thomas Yip, in a research report published on October 9, 2024, maintained a Buy rating on Unicycive Therapeutics Inc. (UNCY:NASDAQ) with a price target of US$2.50. The report follows Unicycive's announcement of the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.

Arce and Yip highlighted the significance of the study results, stating, "UNI-494 showed rapid metabolism, enabling the expected release of nicorandil and its linker." They added, "Importantly, PK results collected in the study showed fast absorption of UNI-494, with rapid metabolism leading to the expected release of nicorandil and its linker."

The analysts noted the safety profile of UNI-494, commenting, "UNI-494 was generally safe and well-tolerated; headache was the most common adverse event (AE), and all AEs were mild with no serious adverse events (SAEs) or AEs leading to withdrawal in Part 1."

Regarding Unicycive's strategic plans, the analysts stated, "Management plans to request a meeting with the FDA by year-end 2024 to review these Phase 1 results and discuss the design of a potential Phase 2 study in patients with acute kidney injury (AKI)."

The report also highlighted the pending milestone for Unicycive's other product candidate, Oxylanthanum Carbonate (OLC), noting, "We await the FDA's formal acceptance of the NDA for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis (we expect by November 2) with a PDUFA date assignment to further narrow OLC's potential approval timing."

H.C. Wainwright & Co.'s valuation methodology for Unicycive is based on a risk-adjusted Net Present Value (rNPV) model. The analysts explained, "We employ a rNPV valuation model to estimate the value of UNCY shares and arrive at our US$2.50 PT based on: (1) about US$2.30 per share for royalties on net sales of OLC in the U.S. and EU (85% PoS, US$149.1M global peak revenue in 2034); and (2) about US$0.25 per share for royalties on net sales of UNI-494 in the U.S. and EU for AKI (20% PoS; US$195M global peak revenue in 2036)."

They added, "In our valuation model, we employ a 14.5% discount rate, which we believe adequately reflects the overall risks of the Unicycive development pipeline. We conservatively assume zero terminal value after the end of the market exclusivity period that runs through 2037."

The analysts also outlined several risk factors, including regulatory, commercialization, market, intellectual property, and funding risks.

In conclusion, H.C. Wainwright & Co.'s maintenance of a Buy rating and US$2.50 price target reflects a positive outlook on Unicycive Therapeutics' potential in developing UNI-494 for AKI and OLC for hyperphosphatemia. The share price at the time of the report of US$0.36 represents a potential return of approximately 594% to the analysts' target price, highlighting the upside potential if the company's clinical development and regulatory plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Unicycive Therapeutics Inc., October 9, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Ed Arce and Thomas Yip , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Unicycive Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Unicycive Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Unicycive Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Unicycive Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: UNCY:NASDAQ, )

Source: Andrew Fein 10/23/2024

H.C. Wainwright & Co. analysts Andrew S. Fein, Matthew Caufield, Dr. Andres Y. Maldonado, and Dr. Ananda Ghosh, in a research report published on October 23, 2024, maintained a Buy rating on DBV Technologies SA (DBVT:NASDAQ) while raising their price target to US$7.00 from US$5.00. The report follows DBV's announcement of regulatory clarity regarding the path forward for its Viaskin Peanut patch.

The analysts highlighted the significance of the FDA agreement, stating, "DBV Technologies has reached an agreement with the FDA regarding the regulatory pathway for the Viaskin Peanut patch in toddlers aged one to three, under the Accelerated Approval pathway."

Regarding the company's development timeline, the analysts noted, "The Biologics License Application (BLA) submission for Viaskin Peanut in this age group is expected to be supported by positive efficacy and safety data from DBV's completed EPITOPE Phase 3 study, as well as additional safety data from the upcoming six-month COMFORT Toddlers supplemental safety study, which is expected to begin in 2Q25."

The report emphasized the strength of DBV's regulatory position, stating, "The FDA has stated that DBV has already satisfied two of the three criteria: the product treats a serious condition, and the product candidate provides a meaningful advantage over available therapies."

The analysts also highlighted progress in Europe, noting, "The EMA confirmed that the successfully completed EPITOPE Phase 3 efficacy and safety trial in the one to three-year-old population, along with positive results from the VITESSE study in the four to seven-year-old population, and a new safety study using the modified circular patch in one to three-year-olds, could support an MAA for the one to seven-year-old indication with the modified patch."

The analysts' valuation methodology for DBV Technologies is based on a composite approach. They explained, "Our US$7 price target is based on an equally weighted composite of: (a) US$5.10/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of US$5.13 discounted back to FY24 at 35%; and (b) an NPV of US$8.52/share with a 13% discount rate and 1% growth rate."

The report included commercial projections, with the analysts stating, "We continue to model initial approval in 2027, with projected initial sales of US$17.5M, growing to US$1,182.8M by 2034."

The analysts also outlined several risk factors, including potential clinical study failures, regulatory approval challenges, and market size uncertainties.

In conclusion, H.C. Wainwright & Co.'s increased price target to US$7 reflects growing confidence in DBV Technologies' regulatory pathway for the Viaskin Peanut patch. The share price at the time of the report of US$0.70 represents a potential return of approximately 900% to the analysts' target price, highlighting the significant upside potential if the company successfully navigates the regulatory process and commercializes its product.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co. DBV Technologies S.A., October 23, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Andrew S. Fein, Matthew Caufield, Andres Y. Maldonado, PhD and Ananda Ghosh, PhD , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of DBV Technologies S.A. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of DBV Technologies S.A.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from DBV Technologies S.A. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from DBV Technologies S.A. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in DBV Technologies S.A. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: DBVT:NASDAQ, )

Source: Streetwise Reports 10/31/2024

Healthcare artificial intelligence (AI) company Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) announced that it has closed a non-brokered private placement for aggregate gross proceeds of CA$1.95 million.

A total of 2,138,766 special warrants of the company were offered at CA$0.75 per special warrant with proceeds of CA$1.6 million. The company also said 466,666 units of the company were offered at CA$0.75 per unit for proceeds of CA$349,999.50.

The company said it intends to use the proceeds for working capital purposes.

"We are very encouraged by the support from our investors with their overwhelming response to the financing and the subsequent over-subscription," Chief Executive Officer Dr. Essam Hamza said. "This money will help expedite our aggressive growth plans over the next year."

Technical Analyst Clive Maund noted on October 9* that the outlook for the company is "outstandingly bright" because it has "positioned itself to revolutionize the healthcare industry using AI and advanced machine learning technologies."

The company "is set to transform the current archaic system so that no longer do patients have to sit for hours in waiting rooms to see a doctor or doctors, and doctors and other healthcare professionals have to suffer a crushing burden of often unnecessary patient visits and tedious repetitive bureaucracy," he wrote. "Treatment AI's platform will take care of most of it."

Healthcare Professionals Worldwide Contribute to AI Engine

Treatment.com AI said it is a company utilizing AI and best clinical practices with a goal to positively improve the healthcare sector and impact current inefficiencies and challenges.

With the input of hundreds of healthcare professionals globally, Treatment.com AI said it has built a comprehensive, personalized healthcare AI engine called the Global Library of Medicine (GLM). With more than 10,000 expert medical reviews, the GLM is designed to provide tested clinical information and support to all healthcare professionals, as well as providing recommended tests (physical and lab), X-rays, and billing codes.

According to the company, the GLM will help healthcare professionals (doctors, nurses, and pharmacists) reduce administrative burdens, creating more time for face-to-face patient appointments.

"AI is set to expedite and streamline the healthcare industry, making it vastly more efficient for the benefit of both healthcare professionals and patients," Maund noted.

The Catalyst: A 'Profound Transformation' in the Industry

AI has an important role to play in the healthcare offerings of the future, a 2019 report from the National Center of Biomechanical Medicine listed in the National Library of Medicine said. "In the form of machine learning, it is the primary capability behind the development of precision medicine, widely agreed to be a sorely needed advance in care."

Healthcare organizations are increasingly turning to the technology to address both clinical and administrative challenges. The combination of generative AI, as noted by Appinventiv in September, and operational tools like those developed by Treatment.com AI are driving this transformation.

Generative AI is "catalyzing a profound transformation within the healthcare industry" by generating synthetic data, predicting patient outcomes, and optimizing treatment plans, all of which revolutionize clinical decision-making processes, Appinventiv reported. This aligns with Treatment.com AI's announced collaboration with SPRYT on September 17 whereby integrating SPRYT’s AI receptionist "Asa" with its GLM has the goal of enhancing patient access to healthcare while reducing administrative burdens.

A CBC report from September 16 said real-world applications of AI in healthcare are already showing promising results. Dr. Muhammad Mamdani, co-author of a study on the topic, expressed optimism about AI's ability to "complement clinicians' own judgment and lead to better outcomes for fragile patients."

According to a report by Markets and Markets, the global AI in healthcare market in total was valued at US$20.9 billion this year and will reach an estimated US$148.4 billion by 2029, a compound annual growth rate (CAGR) of 48.1%.

"The growth of AI in the healthcare market is driven by the generation of large and complex healthcare datasets, the pressing need to reduce healthcare costs, improving computing power and declining hardware costs, and the rising number of partnerships and collaborations among different domains in the healthcare sector, and growing need for improvised healthcare services due to imbalance between healthcare workforce and patients," the report said.

Analyst: A 'Genuine Breakout Soon' for Stock

Maund said its stock charts are also looking "very positive indeed" for the company.

Of particular note is the big upleg late in June and early in July on persistent heavy volume, which broke the price clear above the May high and drove volume indicators steeply higher," the analyst noted. [OWNERSHIP_CHART-10594]

"This is very bullish price/volume action, especially as the volume indicators have not just held up but have actually advanced as the price has reacted back in a normal manner from the early July high to arrive at a support level where it has stabilized above the 200-day moving average in readiness for renewed advance, so the correction looks like a large bull Pennant that, as it is now closing up, promises renewed advance soon," continued Maund, who said holders should stay long and rated the stock a Strong Buy that "is thought worth going overweight on."

"The June-July rally must be classed as a 'preliminary' breakout," he noted. "But that said, the exceptionally bullish price/volume action of recent months does promise a genuine breakout soon that looks set to lead to a sustained and substantial uptrend."

Ownership and Share Structure

According to Sedi.ca, insiders own approximately 8% of Treatment.com AI. Retail investors own the remaining 92%.

The company has 48.84 million outstanding common shares and has 41.3 million free float traded shares.

As of October 31, the market cap is approximately CA$31.75 million. Over the past 52 weeks, the company traded between CA$0.355 and CA$1.11 per share.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Treatment.com AI has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for quotes from the Clive Maund source October 9, 2024

1. For the quote (sourced on October 9, 2024), the Company has paid Street Smart, an affiliate of Streetwise Reports, US$1,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed.

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

( Companies Mentioned: TRUE:CSE; TREIF:OTCMKTS;939:FRA, )

Source: Dr. Douglas Loe 10/31/2024

Leede Financial analysts Dr. Douglas Loe and Siew Ching Yeo, in a research report published on October 30, 2024, maintained their Speculative Buy rating on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) with a price target of US$9.50. The report follows ProMIS's presentation of interim Phase I data for PMN310, its Alzheimer's disease (AD) candidate, at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

The analysts highlighted the positive safety and pharmacokinetic (PK) data, stating, "We were encouraged (though not overly surprised) to see that the mAb was well-tolerated at all five test doses ranging from 2.5mg/kg-to-40mg/kg." They added, "PK analysis of all of these patient cohorts in this single-ascending dose (SAD) trial suggests that once-monthly dosing may be sufficient to sustain mAb levels both in plasma and in cerebrospinal fluid over time."

Regarding dosing efficacy, the analysts noted, "Importantly, ProMIS indicated in the Jul/24 update that even at 2.5mg/kg dosing, PMN310 levels in CSF were over 100x higher than predicted to be necessary to bind to all beta-amyloid oligomers that could accumulate in CSF in diseased patients."

The analysts emphasized the significance of recent industry developments, particularly AbbVie's acquisition of Aliada Therapeutics, stating, "AbbVie's tangible interest in Phase I-stage AD assets shows us that ProMIS could itself be attractive to future suitors if/when it can document direct impact on cognitive impairment in diseased patients."

The report highlighted ProMIS's financial position following its recent equity offering, noting that the company raised US$30.3M with multiple layers of warrant coverage tied to development milestones.

Leede Financial's valuation methodology combines multiple approaches. The analysts explained, "We are maintaining our Speculative Buy rating and one-year PT of US$9.50 on PMN, with our valuation still based on NPV (30% discount rate) and multiples of our F2029 EBITDA/fd EPS forecasts."

They added, "By direct comparison to Aliada's US$1.4B value, PMN shares would notionally be valued on a fully-diluted basis at US$17.65/shr."

In conclusion, Leede Financial's maintenance of their Speculative Buy rating and US$9.50 price target reflects confidence in ProMIS's development of PMN310 and its potential in the Alzheimer's disease market. The share price at the time of the report of US$1.03 represents a potential return of approximately 822% to the analysts' target price, highlighting the significant upside potential if the company's clinical development plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences Inc.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., ProMIS Neurosciences Inc., October 30, 2024

Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.

Description of Disclosure Codes 1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives. 3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. Leede acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst.

Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue.

Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative.

U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

( Companies Mentioned: PMN:TSX; PMN:NCM, )

Source: Streetwise Reports 11/05/2024

Treatment.com AI Inc. (TRUE:CSE; TREIF:OTCMKTS; 939:FRA) has announced the release of its newly updated Medical Education Suite (MES). This release aligns with the company's active participation in a major symposium focused on AI assessment in medical education. The Symposium, hosted by the University of Minnesota Medical School,  drew thought leaders and representatives from over 50 medical schools and national education organizations across the United States and internationally.

The updated MES has been designed to leverage Treatment's proprietary Global Library of Medicine (GLM) to help reduce the administration overhead and associated time and costs for medical schools in running key exams, such as the Objective Structured Clinical Examination (OSCE). Additionally, this updated version of the MES includes "easy to use" features to further support students in their clinical assessment training and exam preparation. This OSCE exam is seen as a critical evaluation used globally to assess the practical skills of medical students. It is now employed in more than 80 countries, with between 200,000 to 300,000 students participating annually.¹

The MES incorporates various AI-driven features, such as automated case generation for OSCE exams, scripts for simulated patients, and instant scoring with personalized feedback. The Suite also introduces new tools, including AI Patient, which supports students preparing for medical exams, and expanded OSCE case packages, which are expected to grow to a library of 100 cases by the end of Q4 2024. Additionally, the AI Prep Tool offers both non-guided and guided exam-simulated modes, assisting students in honing their clinical reasoning.

Kevin Peterson, MD, MPH, Treatment's Chief Medical Officer, delivered a keynote at the Symposium, joining an impressive lineup that includes presenters from Mayo Clinic and the University of Alberta. The company highlights that this Symposium is a crucial opportunity to demonstrate its MES and showcase its growing influence in the field of medical education.

CEO Dr. Essam Hamza emphasized the significance of this event, stating in the press release, "We are excited to showcase our updated medical education software suite at this landmark Symposium. The opportunity to have a positive impact on the medical training of students and, in turn, introduce them to our range of proprietary AI tools is an important inflection point in the company's commercialization timeline."

AI in Healthcare

On October 10, Microsoft emphasized the importance of multimodal AI models for a comprehensive assessment of patient health. The report highlighted the growing importance of using AI to analyze complex, multimodal health data, such as medical imaging, genomics, and clinical records. The integration of these data sources has enabled more precise diagnostics and treatment planning, illustrating the sector's move toward comprehensive AI applications. The healthcare industry has faced challenges like the need for large-scale, integrated datasets and significant computational resources, but advancements have begun to bridge these gaps. Microsoft noted that these developments would help unlock new insights and improve patient care by accelerating innovation and enhancing clinical decision-making across the sector.

On November 4, Forbes reported that AI-powered healthcare tools were no longer merely experimental but were instead delivering real value across the industry. Examples included enhanced diagnostic accuracy through AI algorithms, like those developed by Google Cloud Healthcare, and improved administrative processes through platforms like Cedar's AI-powered billing system. Forbes noted that these developments were reshaping patient care and reducing administrative burdens, offering measurable benefits.

Also, on November 4, Tech Target highlighted the optimism among healthcare professionals regarding generative AI's potential to alleviate administrative burdens. Over 90% of healthcare workers surveyed expressed confidence in generative AI's ability to simplify tasks like prior authorizations and nurse handoff reports. Aashima Gupta from Google Cloud shared insights on these tools' transformative capabilities, while Tony Farah from Highmark Health cited an 85% reduction in provider administrative costs after automating prior authorizations. Helen Waters from Meditech added, "We believe that gen AI and AI overall is transforming how healthcare professionals access and use information to make powerful decisions confidently," reflecting the positive impact of AI tools on healthcare workflows and decision-making.

Company Catalysts

Treatment.com AI Inc. continues to evolve its medical education platform, incorporating advanced AI technologies that could help revolutionize medical education and training. The company is leveraging its Global Library of Medicine, which offers over 10,000 medical reviews and covers more than 1,000 diseases and associated symptoms. These AI-driven tools aim to enhance clinical decision-making while reducing administrative burdens for healthcare institutions.

The updated MES is projected to impact medical training through its comprehensive and AI-enhanced features, as outlined in Treatment's investor presentation. The presentation details the significant market potential, with the AI healthcare market expected to grow from US$11 billion in 2021 to US$187 billion by 2030, according to Statista. In addition to Treatment's announced new functionality, the company has already begun work on further solutions such as AI Doctor in a Pocket and audio/video analysis tools for clinical scoring and diagnostics. The goal of this expanded portfolio is to position the company to help expedite its aggressive growth plans over the next year.

Analysis of Treatment.com AI

Ownership and Share Structure

According to Sedi.ca, insiders own approximately 8% of Treatment.com AI. Retail investors own the remaining 92%. 

The company has 48.99 million outstanding common shares and has 41.3 million free float traded shares.

As of November 4, the market cap is approximately CA$31.35 million. Over the past 52 weeks, the company traded between CA$0.355 and CA$1.11 per share.

¹Source bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org)

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. Treatment.com AI has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000.
2. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Treatment.com AI.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

* Disclosure for the quote from the Clive Maund article published on [Date]

1. For the quoted article (published on [Date]), the Company has paid Street Smart, an affiliate of Streetwise Reports, between US$1,500 and US$2,500.
2. Author Certification and Compensation: [Clive Maund of clivemaund.com] is being compensated as an independent contractor by Street Smart, an affiliate of Streetwise Reports, for writing the article quoted. Maund received his UK Technical Analysts’ Diploma in 1989. The recommendations and opinions expressed in the article accurately reflect the personal, independent, and objective views of the author regarding any and all of the designated securities discussed. No part of the compensation received by the author was, is, or will be directly or indirectly related to the specific recommendations or views expressed

Clivemaund.com Disclosures

The quoted article represents the opinion and analysis of Mr. Maund, based on data available to him, at the time of writing. Mr. Maund's opinions are his own, and are not a recommendation or an offer to buy or sell securities. As trading and investing in any financial markets may involve serious risk of loss, Mr. Maund recommends that you consult with a qualified investment advisor, one licensed by appropriate regulatory agencies in your legal jurisdiction and do your own due diligence and research when making any kind of a transaction with financial ramifications. Although a qualified and experienced stock market analyst, Clive Maund is not a Registered Securities Advisor. Therefore Mr. Maund's opinions on the market and stocks cannot be only be construed as a recommendation or solicitation to buy and sell securities.

¹Source bodies including: https://www.aamc.org/; https://www.uems.eu/; https://www.nmc.org.in/; Education – GMC (gmc-uk.org)

( Companies Mentioned: TRUE:CSE; TREIF:OTCMKTS;939:FRA, )

On-Demand Webinar > Watch Now! SPONSORED BY: TripwireWatch this FREE on-demand webinar to learn how to overcome the top 5 compliance challenges keeping IT directors awake at night! Watch Now! Overc...

Hackers have been around since the early development of computers. Although they have gone by different names at different times, they've been fundamentally known as malicious all-knowing individu...

In a world of ever-advancing technology and development, many company heads often get lost in the bustle and get swept up in the sea of buzzwords that happen to be popular at any given moment. They ...

On-Demand Webcast>Watch Now! SPONSORED BY: TripwireWatch this FREE on-demand webcast and hear from leading IT experts about ways organizations are leveraging technologies such as virtualizatio...

On-Demand Webcast>  Watch Now!SPONSORED BY: SageWatch this FREE on-demand webcast to hear from industry leaders as they walk you through 3 strategies for using ERP to drive productivity and ef...

On-Demand Webinar >  Watch Now!>>SPONSORED BY: AT&TWatch this FREE on-demand webinar to learn how to make the connections between information security and competitive success for yo...

On-Demand Webinar >   Watch Now!>>SPONSORED BY: Juniper NetworksWatch this FREE on-demand webinar to learn how you and your company can get started down the road to reach the pinnacle ...

Skyharbour Resources Ltd. (SYH:TSX.V; SYHBF:OTCQX; SC1P:FSE) has completed its earn-in requirements for a 51% interest at the Russell Lake Uranium Project in the central core of Canada's Eastern Athabasca Basin in Saskatchewan. This comes as the need for more net-zero power is sparking a rebirth of the nuclear industry.

Atlas Lithium Corp. (ATLX:NASDAQ) announced that it has received the operational permit for its Neves Project. Read what this permit, unanimously approved by Minas Gerais government in Brazil, allows Atlas to do.

Poet Amanda Gorman speaks at the inauguration of U.S. President Biden on the West Front of the U.S. Capitol on Wednesday.; Credit: Alex Wong/Getty Images

When Amanda Gorman, a 22-year-old poet from Los Angeles, took to the stage on Wednesday, it was immediately clear why the new president had chosen her as his inaugural poet.

Gorman echoed, in dynamic and propulsive verse, the same themes that Biden has returned to again and again and that he wove throughout his inaugural address: unity, healing, grief and hope, the painful history of American experience and the redemptive power of American ideals.

Where Biden said, "We must end this uncivil war," Gorman declared, "We lay down our arms so we can reach out our arms to one another."

And where Biden called for an American story of "love and healing" and "greatness and goodness," Gorman saw strength in pain: "Even as we grieved, we grew," she said.

Gorman opened by acknowledging the reasons why hope can be challenging. "Where can we find light in this never-ending shade?" she asked.

But she continued: "And yet, the dawn is ours before we knew it. Somehow we do it. Somehow we weathered and witnessed a nation that isn't broken but simply unfinished."

She acknowledged the power of her own presence on the stage in "a country and a time where a skinny black girl descended from slaves and raised by a single mother can dream of becoming president, only to find herself reciting for one."

Like Obama inaugural poet Richard Blanco, who invoked the grand sweep of American geography in a call for unity in "One Today," Gorman dedicated a portion to "every corner called our country" from the South to the Midwest. She ended with an invitation to "step out of the shade."

"The new dawn blooms as we free it," she said. "For there is always light, if only we are brave enough to see it – if only we are brave enough to be it."

Gorman was following in the footsteps of poets like Blanco, Robert Frost and Maya Angelou as she composed the poem "The Hill We Climb" for the inauguration.

She also took her cues from orators like Frederick Douglass, Abraham Lincoln and Martin Luther King, Jr. — people who knew a thing or two about calling for hope and unity in times of despair and division.

Gorman told NPR she dug into the works of those speakers (and Winston Churchill, too) to study up on ways "rhetoric has been used for good." Over the past few weeks, she composed a poem that acknowledges the previous president's incitement of violence, but turns toward hope.

"The Hill We Climb" reads, in part:

We've seen a force that would shatter our nation rather than share it,

Would destroy our country if it meant delaying democracy.

And this effort very nearly succeeded.

But while democracy can be periodically delayed,

It can never be permanently defeated.

In this truth, in this faith, we trust.

For while we have our eyes on the future,

history has its eyes on us.

Gorman, like Biden, had a speech impediment as a child. (Biden had a stutter; Gorman had difficulty pronouncing certain sounds.) She told NPR's Steve Inskeep that her speech impediment was one reason she was drawn to poetry at a young age.

"Having an arena in which I could express my thoughts freely was just so liberating that I fell head over heels, you know, when I was barely a toddler," she said.

For Gorman, a former National Youth Poet Laureate, her struggle to speak provided a connection not only to the incoming president, but also to previous inaugural poets, too.

"Maya Angelou was mute growing up as a child and she grew up to deliver the inaugural poem for President Bill Clinton," she says. "So I think there is a real history of orators who have had to struggle with a type of imposed voicelessness, you know, having that stage in the inauguration."

Barack Obama, Bill Clinton and John F. Kennedy were the only presidents in the past who chose to have poems read at their inaugurations. You can read all the previous poems here.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Michael Ballanger of GGM Advisory Inc. shares his thoughts on the current state of the market.

Dryden Gold Corp. (DRY:TSXV; DRYGF:OTCQB) has announced its participation in three significant mining investment conferences scheduled for November 2024. Read more about the company's plans to showcase major project updates and connect with global investors at these key events.

Technical Analyst Clive Maund shares his opinion on gold's outlook post Trump's election win.

Tim Cook, chief executive officer of Apple Inc., speaks during an event in 2018. Apple is one of 310 companies calling on the Biden administration to slash carbon emissions.; Credit: David Paul Morris/Bloomberg via Getty Images

More than 300 businesses have signed an open letter calling on the Biden administration to reduce greenhouse gas emissions in the United States to at least half of 2005 levels by 2030. That would nearly double a previous target set by former President Barack Obama in 2015, who pledged a 25 to 28% reduction by 2025.

The United States is not currently on track to meet either goal.

The signatories include some of largest companies in the United States, including Walmart, Apple, McDonald's and Starbucks. "A bold 2030 target is needed to catalyze a zero-emissions future, spur a robust economic recovery, create millions of well-paying jobs, and allow the U.S. to 'build back better' from the pandemic," the letter said, echoing the president's economic recovery slogan.

A 50% reduction target would put the Biden administration in line with what groups such as the United Nations and National Academies of Science say is necessary to mitigate the worst impacts of climate change.

In a March statement calling for the same reductions target, the environmental advocacy group Natural Resources Defense Council said such a plan would "help pull the country out of the pandemic-induced recession by putting millions of Americans to work" and inspire more ambitious international climate action ahead of a major United Nations climate conference this November.

Like President Joe Biden's campaign promise to guide the United States to carbon-neutrality by the middle of the century, a 50% emissions reduction target would require steeper emissions cuts than the country has ever achieved.

In 2019, greenhouse gas emissions were approximately 13% below 2005 levels, a decrease of just 1.8% from the previous year.

The Biden administration has identified climate action as one of its top four priorities and has named prominent, experienced Washington insiders, including former Secretary of State John Kerry and former EPA administrator Gina McCarthy, to oversee climate policy efforts at the White House.

As NPR's Danielle Kurtzleben has previously reported, activists on the left are cautiously optimistic about the administration's climate plan after expressing doubts about Biden's climate record during the Democratic primary.

Sunrise Movement, a youth-led climate group that champions the Green New Deal, gave candidate Biden's initial climate plan an "F" grade. Now, the group's executive director Varshini Prakash is publicly celebrating his administration's latest climate-focused $2 trillion infrastructure bill — including its commitment to spend 40% of the infrastructure plan's money on disadvantaged communities and launch a jobs program called the Civilian Climate Corps.

New York Democratic Rep. Alexandria Ocasio-Cortez told NPR earlier this month that she feels that Biden has ultimately come around to the side of progressives on climate issues. She said: "As much as I think some parts of the party try to avoid saying 'Green New Deal' and really dance around and try to not use that term, ultimately, the framework I think has been adopted."

The emphasis on climate comes as a sharp departure from the Trump administration, which withdrew the United States from the Paris Agreement and set no emissions reductions targets.

Signatories to the Paris deal, which Biden rejoined on the day he was sworn into office, are all required to set these targets — formally known as nationally determined contributions, or NDCs.

The agreement also encourages nations to revise their goals every five years, in hopes that the proposals become more ambitious as the cost of environmental reform goes down.

Since the Paris agreement was first agreed to in 2015, though, just fifty of the deal's nearly 200 signatories have submitted revised targets. A recent U.N. analysis of international climate action found that many countries were doing far too little to reduce emissions for the world to avoid the worst effects of climate change.

So far, the White House has not indicated exactly how ambitious their plan will be. An announcement is expected in the coming days as the White House prepares for its Earth Day climate summit with world leaders, scheduled for Thursday, April 22.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A rollercoaster that once sat on the Funtown Pier in Seaside Heights, N.J., rests in the ocean on Wednesday, Oct. 31, 2012 after the pier was washed away by superstorm Sandy.; Credit: Julio Cortez/AP

When Hurricane Sandy swept up the eastern seaboard in 2012, it left a trail of damage from Florida to Maine. Subways were inundated in New York City. Hurricane-force winds tore across New Jersey. Blizzard conditions walloped Appalachia.

The hurricane — also known as Superstorm Sandy — caused an estimated $70 billion in damages in the U.S., mostly from flooding. And while scientists have long believed that some of the carnage was attributable to a warming climate, it's been unclear just how much of a role human-caused warming played in the storm's impacts. New research, published Tuesday in the journal Nature Communications, puts a dollar amount on some of those damages and it's a startling figure.

Using flood maps and sea-level rise measurements, researchers found that human-induced sea-level rise caused an estimated $8 billion in excess flooding damage during Hurricane Sandy and affected an additional 70,000 people.

"I often hear people say when we're trying to help them adapt to increasing coastal flooding, 'Well, it's not going to happen in my lifetime, the sea-level rise won't happen in my lifetime,'" said Philip Orton, a co-author of the study from the Stevens Institute of Technology in New Jersey. "But it's already happening to people. It's already here."

Sea levels at the tip of Manhattan have risen about 8 inches since 1950, according to the National Oceanic and Atmospheric Administration. Estimates range for how much additional sea-level rise is likely to occur, but on average, the expectation is that by mid-century water levels could rise by more than a foot in New York City, compared to the year 2000.

In worst case scenarios, in which humanity does not significantly cut its climate-warming greenhouse gas emissions and the world's ice sheets rapidly melt, sea levels could rise by more than 6 feet by the end of the century, putting hundreds of millions of people at risk worldwide.

Higher water levels mean more areas are susceptible to flooding, storm surge and other problems associated with hurricanes, as well as more chronic flooding from high tides.

The Biden administration has made addressing climate change one of its top priorities. It's proposed a major reconfiguration of the nation's energy and transportation sectors to cut the country's outsized contribution to global warming, with the goal of making the U.S. carbon neutral by the year 2050. Accomplishing that feat will require major federal investments and likely bipartisan support. It's unclear if the administration will be able to procure the latter.

The new study, which joins a growing body of broader attribution science, aims to quantify the cost of inaction and business as usual. Similar studies found that climate change fueled the strength of Hurricane Harvey, increased the risk of Australia's recent unprecedented fire season and contributed to a record-breaking heatwave in Europe.

Scientists have debated whether Hurricane Sandy was made more intense by a warming climate, but it's difficult to know. Generally, there's agreement in the scientific community that hotter global temperatures and warmer ocean waters will lead to more rapid intensification of hurricanes.

Quantifying exactly how much those climatic differences affected a storm like Sandy is difficult. That's why Orton and the team of researchers focused their efforts on sea-level rise, where there's a bevvy of good data. They used that data to model the impacts of Hurricane Sandy in a world without climate change and found the estimated $8 billion difference.

"Increasingly we have the tools to simulate these events and study and quantify the impact of climate change on people's lives," Orton said. "People's lives were dramatically changed by Hurricane Sandy and a lot of them don't realize it had to do with climate change at all."

This content is from Southern California Public Radio. View the original story at SCPR.org.

The data in a QR code is a series of dots in a square grid. Each dot represents a one and each blank a zero in binary code, and the patterns encode sets of numbers, letters or both, including URLs.

Panelists in a discussion on ‘Mobility Megatrends 2050’, highlighted that in the next decade, with electrification, autonomous driving, smart and connected infrastructure, modal diversity, and mobility that is integrated, resilient, shared, and sustainable – powered by disruptive business models, will transform and shape up of the automotive industry. The industry is racing towards a new world, driven by sustainability and changing consumer behaviour, encompassing electric vehicles, autonomous cars, mobility fleet sharing, and always connected.

​So, we think that now we are entering into earnings season with this business update and particularly the banking sector should do well, both PSU and private banks.

Three applied research centers at the Charlotte Research Institute will install instrumentation and conduct experiments at the Eco-Complex, an expansion of innovative waste reduction and waste processing technology already underway at the Complex.

The Catawba County Board of Commissioners, at its January 19, 2010 meeting, joined with other local governments across the region in approving the agreement. The main points of the agreement hinged on Concord and Kannapolis modifying their ability, contained in their IBT certificate, to withdraw 10 million gallons of water per day (MGD) from the Catawba River at all times, by significantly limiting withdrawals during times of drought. The agreement limits withdrawals to 6 MGD during times of most severe drought, or �exceptional� drought; 7 MGD during �extreme� drought; 8.5 MGD during �severe� drought; and 9 MGD during �moderate� drought. Further, the agreement restricts Concord and Kannapolis from withdrawing more than 3 MGD from the Catawba until July 1, 2015, and after they first are withdrawing 5 MGD from the Yadkin River.

A partnership of all fourteen fire departments and all five rescue squads in the county with Catawba County Emergency Services has resulted in a grant from the Federal Emergency Management Agency (FEMA) that will fund a large amount of the costs to purchase new radios to significantly improve communications by and between the fire and rescue agencies and the County�s 911 Communications Center.

The final stages of the 2011 property revaluation process in Catawba County have begun with the presentation of the proposed 2011 Schedule of Values to the Board of Commissioners, and will continue into November, when property owners will receive notice of the new value of their property, and into December and early 2011 when the appeal process begins.

As it continues to note National Emergency Preparedness Month, Catawba County Emergency Services reminds citizens who have family members with special needs, and caregivers of those with special needs, that it�s very important to be prepared in advance to help those with special needs cope with an emergency or disastrous situation.

Catawba County has been awarded one of only two grants presented across the nation, by Motorola and the National Association of Counties (NACo), to local governments that suggested innovative solutions to improve operations within their respective counties. The $30,000 grant will fund the wireless broadband internet capacity needed at Catawba County�s EcoComplex to allow for real-time monitoring between EcoComplex laboratories, universities and businesses.

Employees with 25 or more years of service were recognized at the twenty-sixth annual Quarter Century Club lunch at the Catawba Country Club. Many current members of the club celebrated with retired County employees, who also served with the County for 25 or more years. Catawba County formed the Quarter Century Club in 1986.

Beginning July 1, 2011, computer equipment and televisions will be banned from disposal in North Carolina landfills, under a law passed last year by the General Assembly. Catawba County will provide four one-day electronics recycling collection events in fiscal year 2011-2012, free of charge. All residents of Catawba County will have access to these electronics recycling events, including those who live in the cities and towns in the county.

Internal Systems Analyst Scott Klinger was recognized, in part, for integrating a new billing program that resulted in improved efficiencies across the organization.

Catawba County Government renewed an annual tradition on March 22nd, honoring employees with 25 or more years of service at the twenty-seventh annual Quarter Century Club lunch. Catawba County formed the Quarter Century Club in 1986. A highlight of this year�s program was the recognition of twelve new Quarter Century Club members.

The EcoComplex is a system that recovers all useable products and by-products from a group of private and public partners located in a close-knit defined area. This group of partners works together to use each other�s waste products either as a source of energy (electricity, steam, or heat) or as a raw material for the production of their own product (pallets, lumber, compost, brick shapes/art). The EcoComplex is also focused on making and using �green� energy and on economic development.

Catawba County Emergency Medical Services names Employees Of Year.

Smart Electric North America, LLC is opening its North American headquarters in Conover, NC at 1550 Deborah Herman Road SW. SENA plans to build market share by supplying quality components and finished goods to the top tier lighting companies in the US first; then abroad.

2012 Catawba County Employee Of The Year, Ona Scruggs, recognized for patience, understanding, listening in stressful arena.

A new agreement extends borrowing privileges at Lenoir-Rhyne University Library to registered users of Hickory Public and Catawba County Libraries.

Catawba County Director of Utilities and Engineering Barry Edwards has been named one of the winners of the 2013 Energy Leadership Awards by the Business Journal of Charlotte.

Catawba County will mail data verification, income and expense request, to property owners as 2015 revluation process continues on May 17, 2013. Owners are requested to verify the information found on the data verification sheet, provide pertinent additional information and make any necessary corrections, and return the form to the revaluation office. http://www.catawbacountync.gov/events/revalmailer13.asp

Catawba County Home Health is empowering older adults to lower their risk of falling through a new service called Smart Moves.

Annual Financial Report for Fiscal Year 2012-2013 shows Catawba County improved its financial position with conservative approach.

; Credit: /Michelle Kondrich for NPR

In Jasmine Williams' family, graduating from the University of Michigan is a rite of passage. Her parents met on the campus, and her older sister graduated from the school a few years ago. She remembers sitting bundled up in the family section for that graduation. "It was overwhelming to feel so many people that proud," she says, "I remember sitting there watching her, and that was probably the first time I was like, 'OK, yeah, I like this. I can't wait to do this.'

This year, Williams' own graduation will look a bit different. The main undergraduate ceremony will be all virtual, though the university has invited students to watch that ceremony from the football stadium on campus known as the Big House. There will be no family members in attendance, and students will be required to have a negative COVID-19 test result to enter.

"I think it's hard not to downplay it when it's reduced to a Zoom," says Williams. But come Saturday, she's planning on donning her cap and gown and heading to the stadium with friends. "Knowing that we are going to the Big House to watch together as a class makes everything way more enjoyable for the weekend; to be able to at least get some remnants of what I witnessed years ago with my sister." Her family plans to host a streaming party from their home in Detroit.

As an academic year like no other comes to an end, colleges and universities are celebrating their graduates in a variety of ways. Some schools, like the University of Idaho and Virginia Tech are hosting multiple smaller, in-person ceremonies to comply with social distancing mandates. Others, like Iowa State, are hosting large ceremonies in football stadiums and outdoor arenas. There's also a handful that are doing virtual-only again, like the University of Washington and Portland State University. At some schools, including the University of Michigan and Emmanuel College in Boston, in-person events are restricted to just graduates; family and friends have to watch from a livestream.

For lots of students, the effort to be in-person is greatly appreciated. "You work hard those four years, you dream of that day, getting to graduate in-person and walk across the stage," says Jamontrae Christmon, a graduating senior at Tennessee State University in Nashville. For most of the year he assumed graduation would be virtual. He even sent out his graduation announcements to friends and family — and left the date off. Weeks later, he learned TSU would actually hold a May 1st in-person ceremony in the football stadium.

"I haven't been sleeping much this week at all. I'm just happy. Excited," says Christmon.

But planning for an event in an ongoing public health emergency has proven to be stressful. Steve Bennett, the chief of staff for academic affairs at Syracuse University, has worked to create commencement ceremonies that are as close to a normal year as possible.

"This may be the single most challenging special event that our team has put together, maybe ever," explains Bennett. "And it's because we keep having to plan towards a moving target."

Syracuse's plan for graduation is to have multiple smaller commencement ceremonies in their stadium; everyone in attendance has to be fully vaccinated or show proof of a recent negative COVID-19 test. According to state guidance, the stadium can only reach 10 % capacity, so graduates are limited to two guests per person. Despite the restrictions, the team that planned the ceremonies is determined to make it one that the class of 2021 deserves.

"The students have been through a lot this year. Graduating seniors lost a number of student experiences due to pandemic conditions that are important to them," says Bennett. That's why having the in-person component was essential. "It was really important to the university, given [the seniors'] commitment to us, that we have a commitment to them."

At California Lutheran University, in Thousand Oaks, Calif., graduation will be celebrated as a drive-in style event at the Ventura County Fairgrounds. Each graduate can bring one carful of people to the fairgrounds parking lot, which can accommodate up to 700 vehicles. Inspired by the city's drive-in concert events, there'll be a stage with speakers and a jumbo screen.

"That's ultimately what led us to our decision to have it at the fairgrounds. Since it's a drive-in and they're staying in their cars, they were allowed to bring family... that was just really important to us," says Karissa Oien, who works in academic affairs at California Lutheran University and is the lead organizer for the drive-in commencement. She's been planning the university's ceremonies for 13 years, and knows how important graduation can be — not just for students, but for those who helped them along the way as well.

"We wanted to have that moment again. Where the families can see their students cross the stage and be there with them."

Jamontrae Christmon, the graduating senior from Tennessee State University, will have his parents, an uncle and one of his sisters there with him at Hale Stadium. "It's just something about your parents being there," says Christmon, "you want to look into the audience and maybe see your parents and you hear them scream your name when they call your name to walk across the stage."

As the day gets closer, Christmon says he's been thinking about the moments of self-doubt he had along the way. "I could have easily said 'I'm not cut out for college' and just gave up, but I didn't." He says his family was a big part of that motivation.

"Not many in my family even attended college, let alone graduated. So this is a big deal," says Christmon. "To me it means I broke the cycle. And that's what they always wanted."

He expects his mother will cry, and likely, he will too.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A hazing-related student death at Bowling Green State University has renewed conversations about hazing on college campuses.; Credit: Adam Lacy/Icon Sportswire via Getty Images

There were zero reported deaths from college hazing incidents in 2020, but as campuses reopen to students, there have already been two hazing-related deaths this year. Eight men face a range of charges, including involuntary manslaughter, reckless homicide, evidence tampering and failure to comply with underage alcohol laws, after Stone Foltz, a sophomore at Bowling Green State University, died on March 7 of alcohol poisoning.

At a news conference on April 29, Wood County Prosecutor Paul Dobson described the fraternity event in which initiates were told to drink 750 milliliters of hard alcohol — or about 40 shots, according to Hank Nuwer, author of Hazing: Destroying Young Lives. Dobson said Foltz's death was "the result of a fatal level of alcohol intoxication during a hazing incident."

Experts like Nuwer are concerned that as students return to in-person learning and are eager to take part in "the college experience," more hazing-related deaths may be on the way.

"There seems to be a disconnect — not seeing that alcohol-related hazing can kill," he says.

Nuwer is a professor emeritus of journalism at Franklin College and the author of five books on hazing. He spoke with NPR's All Things Considered about how the Stone Foltz case could reshape hazing prosecution, how college campuses create a "perfect storm" for hazing and how to put an end to the practice, once and for all.

This interview has been edited for length and clarity.

Interview Highlights

On the legal history of prosecuting hazing

There've been charges all along, but often they get dropped or they're unsuccessful. I would consider this to be a landmark case because of the possibility of at least five years of imprisonment, if the prosecutor is successful.

We have 44 state laws out there on hazing, but some are very, very weak. And Ohio's is weak now, but they're trying to strengthen it after a death at Ohio University [in 2018] and now Bowling Green.

On what the return to college campuses means for hazing

What I'm seeing is, in effect, we have two freshmen classes in that the sophomores have been taking online classes. Now they're going to be out there, and they haven't had any hazing or alcohol education programs. They're coming out there with a gusto because now they're the people of status, who have power over these pledges. And then the regular freshman class is coming in, all excited as usual, and we've seen so many times where a death occurs within the first couple of days of the students on campus, sometimes before they've taken a single class.

On the challenges to end fraternity hazing

In my opinion, campuses are the perfect storm for something like this because we're all about status and power. All of these obstacles have led to today, when alcohol has been added to the mix. There wasn't a single alcohol death before 1940. Now, it's one of the most major [causes of hazing-related deaths]. There were 62 deaths from 2009 to 2021; 39 were alcohol related.

On whether this is a chance for colleges to reset this part of campus culture

I want a hard approach. You have to go after the alumni who are encouraging this. You have to punish all of the hazing — not temporarily. This tradition has to stop, and it can't be looked at as tradition. As Mr. [Paul] Dobson, the prosecutor, is doing in the Stone Foltz case: You have to prosecute to the fullest extent [of the law].

This content is from Southern California Public Radio. View the original story at SCPR.org.

Students wave goodbye during dismissal at Yung Wing School P.S. 124 on March 25, 2021 in New York City.; Credit: Michael Loccisano/Getty Images

New York City schools will reopen in full this fall with no options for virtual learning.

Mayor Bill de Blasio made the announcement during an appearance Monday on MSNBC, saying, "You can't have a full recovery without full-strength schools, everyone back sitting in those classrooms."

De Blasio said the nation's largest school district will meet in person five days a week, with no remote option available. New Jersey has similar plans, and other states want to limit remote lessons as well.

While the decision in New York is being celebrated as an important milestone on the path to returning to some level of normalcy from the pandemic, some parents remain fearful about sending their children back to in-person learning.

Meisha Porter, chancellor of the New York City Department of Education, has heard those concerns firsthand, but says "our schools have been the safest place in the city."

In an interview with NPR's Morning Edition, Porter said that with New York City in the process of a full reopening, "it's important that our schools be fully open, too."

Porter said the city would not make the vaccine a requirement for staff and teachers, but said more than 70,000 employees have already received at least one dose. The city will continue to monitor the health and safety of children, teachers and staff, she said, "but we know our schools have been safe and we need our children back."

Interview Highlights

What do you say to parents who are still really worried about the virus and may not want their kids to return, especially elementary aged kids who don't have access to a vaccine?

I say what we've said over and over again. You know, this past week, we've been at 0.3% — our seven-day positivity rate. Our schools are the safest place. And I've always said nothing, absolutely nothing, replaces the interaction and the learning that happens between a student and teacher in our classrooms. And so what I say to parents, as a parent, is we're going to continue to be in conversations. We're going to continue to make decisions around health and safety. We're going to continue to do those things that parents need us to do, that I need to ensure that we do, to make sure our buildings remain safe and we can get our babies back.

Is part of that effort a consideration about making the vaccine a requirement for staff and teachers?

At this moment, we're not making it a requirement, but we are encouraging [staff and teachers to get vaccinated], and we're going to really work with the city to provide access for students and families and teachers, as we've done over the last couple of months. And so right now, we're pushing and encouraging our staff to get vaccinated. ...

But I mean, wouldn't that help if you had 100%? I mean, children are required to show proof of of immunizations of vaccines to go to school. Why not maintain the same line for teachers and staff?

... I would say this, that we are not in a place where we want to, at this moment, mandate the vaccine. We want to continue to encourage. We all know that folks have had concerns about vaccines, and we want to continue to encourage that vaccines are safe and they are effective. I've been vaccinated along with the 70,000 DOE employees that have been vaccinated. And so we're not, at the moment where we are going to require it.

Have you heard from families who've come to rely on being able to have their kids, their teenagers, working while in school? There's evidence that those with that kind of economic need are those who want to continue with remote learning or some kind of hybrid.

I can tell you that I haven't heard that from families, that they want to they want remote learning so that their teenagers can continue to work. But I know, that that may be a reality for some families. And one of the things that we're doing this summer is increasing access to summer youth employment, increasing access to our learning-to-work programs for our young people, because we know how important it is for some young people to work. But it is equally, if not more important, that they maintain learning and have a connection to a strong and sound education, and we'll continue to do that through learning to work throughout the school year.

What about those students who have found that remote learning just works better for them? I mean, whether they are kids who have struggled socially in school environments, who have been bullied or kids with learning challenges who appreciate just being able to focus away from other students in the classroom. Are there any plans to come up with ways to better address their needs in the future?

So what we're looking forward to is leveraging what we've learned from remote learning as an innovation in our system as we move forward in return. And I think that's what's going to be important for us.

Do you know what that innovation is going to look like?

It's going to look like access to courses across schools and districts, breaking down district lines and walls, high-level courses, enrichment opportunities. You know, remote learning has expanded the universe of what schools should look like.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A customer walks behind a sign at a Nordstrom in Coral Gables, Fla., store seeking employees in May.; Credit: Marta Lavandier/AP

Two organizations filed a lawsuit against Indiana Gov. Eric Holcomb in an attempt to block the state's push to end pandemic unemployment benefits on June 19.

Indiana Legal Services, an organization providing free legal assistance, and the Concerned Clergy of Indianapolis filed the lawsuit on behalf of five unnamed plaintiffs who are set to lose their jobless benefits. The complaint was filed Monday in Marion County Superior Court.

This lawsuit may be the first of its kind that aims to stop states from ending these benefits earlier than Congress mandated.

The unemployment insurance program "has served as a vital lifeline for thousands of Hoosiers," the complaint, reviewed by NPR, says. "By prematurely deciding t0 stop administering these federal benefits, Indiana has violated the clear mandates 0f Indiana's unemployment statute—to secure all rights and benefits available for unemployed individuals."

Indiana is one of 25 Republican-led states that decided to end jobless aid in an effort to get people to return to work. Indiana and seven other states are set to end expanded unemployment benefits as soon as this weekend. This is despite Congress's authorization for extra payments until early September.

Those benefits include the extra $300 a week in federal aid and the special pandemic program for gig workers that allows them to receive jobless benefits. Ordinarily, independent contractors wouldn't be eligible.

Plaintiffs, as well as many other Indiana residents, rely entirely on the unemployment benefits to pay for food and rent and to care for their families, the complaint alleges.

Attorneys in this case are requesting the judge approve a preliminary injunction that would allow people to receive their benefits while the case continues.

Holcomb says it's time to get back to work

Holcomb told The Indianapolis Star that people no longer need unemployment benefits as the state has a plethora of jobs open.

"Eliminating these pandemic programs will not be a silver bullet for employers to find employees, but we currently have about 116,000 available jobs in the state that need filled now," he said.

According to the governor's office, Indiana's unemployment rate has recovered to 3.9% after climbing to 17% at the height of the pandemic.

The lawsuit challenges Holcomb's assertion.

Each of the five plaintiffs say they are unable to return to work due to lingering injuries or disability, health conditions that put them at risk for COVID-19 exposure, dependent children at home and no childcare available, or no positions that are available in their career field.

Workers of color feel the loss of unemployment the most

The National Employment Law Project says ending these jobless benefits early threatens the livelihoods of workers of color the most.

Millions of Americans still heavily rely on jobless aid as the country slowly reopens from pandemic-induced lockdowns, according to the organization.

As of May 22, more than 15.3 million people still needed some form of unemployment benefit—nearly twice the number who received payments when the aid programs began in late March 2020, NELP said.

According to its analysis, over 46% of unemployment insurance recipients in the states ending the programs early are people of color.

"The brunt of the impact will be felt by Black, Latinx, Indigenous, and other people of color," NELP says.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Cancer-causing chemicals that occur naturally in foods are far more numerous in the human diet than synthetic carcinogens, yet both types are consumed at levels so low that they currently appear to pose little threat to human health, a committee of the National Research Council said in a report released today.

A bold national initiative is needed to reduce the enormous health burden of sexually transmitted diseases (STDs) in the United States, according to a new report from a committee of the Institute of Medicine.

Widespread reforms are needed to ensure that all children are equipped with the skills and instruction they need to learn to read, according to a new report from a committee of the National Research Council.